Atlas Trials

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Clinical trial NCT01625182 · COMPLETED

Trial details

NCT number
NCT01625182
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Start date
2012-12-22
Primary completion
2016-09-03
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.